Literature DB >> 12919831

Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics.

Dominick Mendola1.   

Abstract

Large-scale, renewable supplies of chemical constituents derived from marine invertebrates have limited development of potential new natural product drugs. This paper describes the development of two in-sea aquaculture systems designed and engineered for production of large quantities of biomass for two species of marine invertebrates desired for their natural product chemical constituents. The two invertebrates and their products were: (1) the cosmopolitan, arborescent bryozoan Bugula neritina (Phylum Bryozoa) for its anticancer chemical constituent bryostatin 1; and (2) Ecteinascidia turbinate (Phylum Tunicata) the source of anticancer ecteinascidin 743. For the third invertebrate Phylum Porifera, and its representative sponge Acanthella cavernosa (desired for its anti-parasitic and anti-infective kalihinols) in-sea systems were not developed in favor of controlled environment tank aquaculture systems. For the bryozoan and tunicate, projected economics for commercial-scale in-sea production proved cost effective. This was in contrast to the controlled environment sponge culture tank system, which did not prove to be economical due to inherent slow growth and low natural product yields of the sponge in culture. A non-destructive method for "milking" natural product chemicals from sponges was tested and is described.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919831     DOI: 10.1016/s1389-0344(03)00075-3

Source DB:  PubMed          Journal:  Biomol Eng        ISSN: 1389-0344


  32 in total

1.  Translating Nature's Library: The Bryostatins and Function-Oriented Synthesis.

Authors:  Paul A Wender; Brian A Loy; Adam J Schrier
Journal:  Isr J Chem       Date:  2011-03-24       Impact factor: 3.333

Review 2.  Exploitation of marine algae: biogenic compounds for potential antifouling applications.

Authors:  Punyasloke Bhadury; Phillip C Wright
Journal:  Planta       Date:  2004-06-24       Impact factor: 4.116

Review 3.  Bryostatins: biological context and biotechnological prospects.

Authors:  Amaro E Trindade-Silva; Grace E Lim-Fong; Koty H Sharp; Margo G Haygood
Journal:  Curr Opin Biotechnol       Date:  2010-12       Impact factor: 9.740

Review 4.  Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associants.

Authors:  Ocky K Radjasa; Yvette M Vaske; Gabriel Navarro; Hélène C Vervoort; Karen Tenney; Roger G Linington; Phillip Crews
Journal:  Bioorg Med Chem       Date:  2011-07-26       Impact factor: 3.641

5.  Hypothesized kinetic models for describing the growth of globular and encrusting demosponges.

Authors:  Detmer Sipkema; Nejla A M Yosef; Marcin Adamczewski; Ronald Osinga; Dominick Mendola; Johannes Tramper; René H Wijffels
Journal:  Mar Biotechnol (NY)       Date:  2006-01-01       Impact factor: 3.619

Review 6.  Sponge-associated microorganisms: evolution, ecology, and biotechnological potential.

Authors:  Michael W Taylor; Regina Radax; Doris Steger; Michael Wagner
Journal:  Microbiol Mol Biol Rev       Date:  2007-06       Impact factor: 11.056

Review 7.  Farming sponges to supply bioactive metabolites and bath sponges: a review.

Authors:  Alan Duckworth
Journal:  Mar Biotechnol (NY)       Date:  2009-07-08       Impact factor: 3.619

8.  Changes in bacterial communities of the marine sponge Mycale laxissima on transfer into aquaculture.

Authors:  Naglaa M Mohamed; Julie J Enticknap; Jayme E Lohr; Scott M McIntosh; Russell T Hill
Journal:  Appl Environ Microbiol       Date:  2007-12-21       Impact factor: 4.792

9.  Culture of explants from the sponge Mycale cecilia to obtain bioactive mycalazal-type metabolites.

Authors:  Jose L Carballo; Benjamin Yañez; Eva Zubía; Maria J Ortega; Cristina Vega
Journal:  Mar Biotechnol (NY)       Date:  2009-11-26       Impact factor: 3.619

Review 10.  Towards commercial production of sponge medicines.

Authors:  Marieke Koopmans; Dirk Martens; Rene H Wijffels
Journal:  Mar Drugs       Date:  2009-12-02       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.